GLP-1 FAQ: Every Question, Answered

GLP-1 (glucagon-like peptide-1) is a hormone the gut releases after eating. GLP-1 medications are synthetic versions that activate GLP-1 receptors to suppress appetite, slow gastric emptying, and improve blood sugar.

Glucagon-like peptide-1 — named because it shares structural similarity to the peptide glucagon, despite having opposite functional effects on blood sugar.

GLP-1 medications activate receptors in the brain (appetite reduction), stomach (slowed emptying), and pancreas (glucose-dependent insulin, glucagon suppression). The combined effect produces weight loss and improved blood sugar control.

"GLP-1s" is shorthand for GLP-1 receptor agonist medications — the drug class that includes semaglutide, tirzepatide, liraglutide, and dulaglutide.

Yes for most patients. Common side effects (nausea, GI) are usually mild and improve. Serious events (pancreatitis, gallbladder, kidney) are rare. Contraindicated in patients with thyroid cancer history or pancreatitis history.

Three main mechanisms: reduce appetite via brain receptors, slow stomach emptying so meals satisfy longer, reduce food cravings ("GLP-1 voice").

Increasingly considered long-term medications, similar to blood pressure or cholesterol drugs. Stopping leads to most patients regaining weight.

Appetite changes within 1-2 weeks. Visible weight loss starts week 4-8 once therapeutic dose is reached.

FDA-approved: semaglutide (Wegovy, Ozempic, Rybelsus), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity). Pipeline: retatrutide, orforglipron, survodutide, pemvidutide.

Yes. Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist.

Yes — partially. Mounjaro is tirzepatide, a dual GLP-1/GIP receptor agonist.

Yes. Wegovy is high-dose semaglutide approved for weight loss.

Yes — it's tirzepatide, a dual GLP-1/GIP agonist approved for weight loss.

Yes. Trulicity is dulaglutide, a once-weekly GLP-1 RA.

Yes. Saxenda is liraglutide, a daily GLP-1 RA approved for weight loss.

Yes. Victoza is liraglutide for type 2 diabetes.

Yes. Rybelsus is the only FDA-approved oral GLP-1 (oral semaglutide).

No. Metformin is a biguanide that reduces liver glucose production. Not a GLP-1.

Yes — partially. Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors. Pipeline drug expected 2026.

Tirzepatide (~21% weight loss). Pipeline retatrutide showed ~24% in Phase 2.

Branded list: $1,000-1,400/mo. Compounded online: $179/mo. With insurance copay: $25-150/mo typically.

Compounded semaglutide via online providers ($179/mo all-in).

For type 2 diabetes: yes, broadly. For weight loss: many commercial plans cover Wegovy/Zepbound with PA. Medicare doesn't cover for weight loss alone (except CV indication).

$1,349/month list price.

$1,069/mo autoinjector. $349/mo via LillyDirect vials.

Not yet. Patents expire 2031-2033. Compounded versions are alternatives now.

Costco partners with Sesame for compounded GLP-1 at member-discounted rates (~$179/mo).

Most common: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), decreased appetite (universal/intended), fatigue, headache.

GLP-1 does not directly cause hair loss. Telogen effluvium from rapid weight loss does. Mitigate with high protein, slow titration.

No clear evidence in humans. Rodent thyroid C-cell tumor signal led to a boxed warning. Contraindicated in patients with personal/family MTC or MEN 2 history.

Yes — and it reduces cardiovascular events in patients with established heart disease (SELECT trial: 20% MACE reduction).

Most concerning long-term: gallbladder disease (mild excess), pancreatitis (rare), and animal-only thyroid signal. Lean mass loss is mitigated with protein and resistance training.

Peaks weeks 1-4 and after dose escalations. Improves substantially by month 3-4 at maintenance.

Yes. Multiple licensed telehealth providers prescribe GLP-1 (mostly compounded sema/tirz) starting at $179/mo.

For value: compounded sema at $179/mo. By branded provider: Mochi, Hers, Ro, depending on insurance and drug preference.

Yes when prescribed by licensed clinicians via established platforms. Avoid sites that ship from outside US, sell "research peptides," or skip the clinician evaluation.

Online intake takes 10-15 min. Clinician review same-day to 48h. Medication ships in 5-7 days.

Search local endocrinologists, weight-management clinics, or telehealth providers covering your state.

Yes — Rybelsus (oral semaglutide) is FDA-approved for diabetes. Pipeline orforglipron expected 2026.

Products marketed as "GLP-1 patches" are dietary supplements, not GLP-1 medication. They do not produce real GLP-1 weight loss.

Highest evidence: psyllium husk fiber (10-15g/day). Modest effects only.

No clinical evidence for meaningful weight loss. Contains lemon and saffron extracts marketed for "natural GLP-1 production."

Generally low-risk because amounts are small. Ingredient-specific concerns (bitter orange in some, drug interactions with berberine).

Using doses below standard FDA-approved schedule — typically 25-50% of standard. Reduces side effects, useful for maintenance.

Draw sub-standard doses from compounded vials with insulin syringes. Use our calculator at /microdosing/.

Yes, but less than full doses. Realistic 5-10% weight loss vs. 15-22% at full dose.

Off-label investigational use. Limited evidence; some clinicians prescribe based on anti-inflammatory effects of GLP-1.

High-protein (0.7-1g/lb goal weight), 25-30g fiber, 2-3L water, modest deficit, smaller frequent meals.

High-fat fried foods, large portions, sugary drinks, excessive alcohol, ultra-processed snacks.

Dry wines, light beers, spirits with seltzer/lime. Avoid sugary cocktails. Lower tolerance — drink less than usual.

Resistance training 2-3x/week (preserves muscle), 7-10K steps daily, 1-2 cardio sessions for heart health.

Yes. Watch for reflux at high intake. Caffeine itself is fine.

Contraindicated during pregnancy. Wait 2 months after last semaglutide dose before conceiving.

Limited data. GLP-1 unlikely to be orally absorbed by infant if transferred. Discuss with prescriber.

Slowed gastric emptying matters for anesthesia. Most surgeons recommend pausing 1 week before non-emergency surgery.

Contraindicated with personal/family medullary thyroid carcinoma or MEN 2. Hashimoto's/Graves' is generally compatible — discuss with prescriber.

Can be very effective. Weight loss often improves PCOS symptoms (cycle regulation, fertility, insulin resistance).